CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The Phase III RESTORE-1 study is highly innovative in its use of wearable sensors and the FDA-cleared AF digital biomarker developed by physIQ.

The DIVE study is a retrospective and prospective cohort, controlled, single-center, phase 1 study with a primary objective of evaluating the safety and radiographic outcomes associated with using IRRAS' IRRAflow system compared to the current standard of care with external ventricular drains.

Restore EF Study is a prospective, multi-center study evaluating the best practices in contemporary PCI practice, including more complete revascularization. Participants received an Impella-supported high-risk PCI, also called an “on-pump PCI,” at one of 22 sites across the United States between August 2019 and May 2021.

"The data collected with the CM-1500 in the earlier phases of the apheresis trial was encouraging and incredibly valuable for improving accuracy of the CM-1600 Relative Index," said Donald Gregg, VP of Zynex Monitoring Systems.

"These data demonstrate that the Hemopurifier can effectively capture a wide range of clinically relevant SARS-CoV-2 variants," said Charles J. Fisher, M.D., Chief Executive Officer of Aethlon Medical.

"The publication of Cryocure-2 data is seen as a significant step in the validation of Adagio's ULTC technology," said Olav Bergheim, President and CEO of Adagio Medical.

Artivion advises the trial is designed to support the company's forthcoming application to the U.S. Food and Drug Administration for premarket approval of the AMDS.

Embrace Hydrogel Embolic System is an investigational device intended to be used to embolize peripheral arterial bleeds in vessels ≤ 6 mm